Montreal's research community has achieved a monumental milestone in cancer immunotherapy with the publication of a groundbreaking study in Nature. Researchers from the Institut de recherches cliniques de Montréal (IRCM), in close collaboration with the Université de Montréal and McGill University, have unveiled SLAMF6—Signalling Lymphocytic Activation Molecule Family member 6, also known as Ly108—as a novel drug-targetable suppressor of T cell immunity against cancer. This discovery addresses a critical gap in understanding why many patients fail to respond to existing immunotherapies, offering hope for more effective treatments.
The study, titled "SLAMF6 as a drug-targetable suppressor of T cell immunity against cancer," demonstrates how this self-interacting receptor on T cells acts as an internal brake, independent of tumor cell involvement. By developing specialized monoclonal antibodies that block these interactions, the team showed enhanced T cell activation and tumor control in preclinical models. This positions Canadian higher education institutions at the forefront of global oncology research, fostering opportunities for interdisciplinary collaboration and innovation.
🔬 Decoding SLAMF6: From Ambiguous Receptor to Clear Inhibitory Target
SLAMF6 belongs to the Signaling Lymphocytic Activation Molecule (SLAM) family of receptors, which are known for their roles in immune cell communication. Historically, SLAMF6's function in T cells has been puzzling, exhibiting both activating and inhibitory signals depending on context. However, the Montreal team's rigorous experiments clarified its dominant role as an inhibitory checkpoint.
Expressed preferentially on progenitor or stem-like exhausted T cells (Tpex)—those with potential for revival post-checkpoint blockade—SLAMF6 engages in homotypic cis interactions. This means SLAMF6 molecules on the same or adjacent T cell surfaces bind together, recruiting the phosphatase SHP-1 to dampen T cell receptor (TCR) signaling. Step-by-step: upon T cell activation in the tumor microenvironment, dense T cell clustering triggers these cis bonds; SHP-1 dephosphorylates key signaling molecules like ZAP-70 and ERK, halting proliferation, cytokine release (e.g., IFN-γ, TNF-α), and cytotoxic granule exocytosis; this leads to T cell dysfunction and exhaustion.
In knockout mice lacking SLAMF6, T cells displayed hyperactivation: increased cytokine production upon stimulation, better proliferation, and superior tumor rejection in models like E.G7 (OVA-expressing thymoma) and B16-OVA (melanoma). Human primary CD8+ T cells mirrored this, with blocking antibodies preventing exhaustion after repeated antigen exposure.
This mechanism's independence from tumor SLAMF6 expression is revolutionary, broadening its therapeutic applicability across cancers.
The Research Powerhouse: IRCM and Montreal's Academic Ecosystem
Led by senior author Dr. André Veillette, a professor in the Department of Medicine at both Université de Montréal and McGill University, and director of IRCM's molecular oncology unit, the team includes first author Bin Li and contributors like Ming-Chao Zhong, Cristian Camilo Galindo, Jiayu Dou, Jin Qian, Zhenghai Tang, and Dominique Davidson. IRCM, affiliated with Université de Montréal's Faculty of Medicine, exemplifies translational research hubs in Canadian higher education.
Funding from the Canadian Institutes of Health Research (CIHR), Terry Fox Research Institute, BioCanRx, Québec’s Ministry of Economy, Innovation and Energy, and the Canadian Foundation for Innovation underscores government commitment to biomedical excellence. This Nature publication elevates Montreal's status, rivaling global leaders like MD Anderson, and attracts top talent to higher-ed research jobs in immunology and oncology.
Dr. Jean-François Côté, IRCM's president, hailed it as "a new chapter in immunotherapy," highlighting precision therapeutics' impact.
Experimental Breakthroughs: Mouse Models and Human Validation
The study's multi-layered approach combined genetic knockouts, antibody engineering, and advanced assays. In vivo, Slamf6-deficient OT-I CD8+ T cells cleared tumors faster in adoptive transfer models. Blocking monoclonal antibodies (mAbs)—optimized for cis disruption—yielded even stronger results: reduced tumor burden by over 70% in humanized mouse models, fewer PD-1+ exhausted T cells, and boosted Tpex populations.
- Flow cytometry revealed 2-3 fold increases in IFN-γ and Granzyme B.
- Proximity ligation assays confirmed cis interactions.
- Immunoblots showed SHP-1 dependent phospho-inhibition.
Human Jurkat T cells and primary CD8+ T cells responded similarly, with mAbs outperforming prior SLAMF6 tools. No cytokine release syndrome was observed, enhancing safety profiles.Read the full Nature study here.
Addressing Immunotherapy Resistance: A Game-Changer for Non-Responders
Checkpoint inhibitors like anti-PD-1 (e.g., pembrolizumab) succeed in ~20-30% of patients, leaving many with "cold" tumors lacking T cell infiltration. SLAMF6 blockade reinvigorates Tpex cells, promoting infiltration and function. Preclinical synergy with PD-1 blockade suggests combos could expand response rates to 50%+ in melanoma, lung cancer, and beyond.
In Canada, where cancer incidence rises (e.g., 233,900 new cases in 2025 per Canadian Cancer Society), this could transform outcomes. For higher ed, it spurs demand for PhD/postdoc roles in higher-ed postdoc positions focused on immuno-oncology.
Broader Implications for Canadian Cancer Research Landscape
Montreal's ecosystem—bolstered by McGill's Rosalind and Morris Goodman Cancer Centre and UdeM's CRCHUM—fosters such breakthroughs. CIHR's ~$1.2B annual health research investment supports this, but challenges like funding competition persist. This paper highlights needs for more Canada-specific academic jobs in translational medicine.
Stakeholders: Patients gain hope; pharma eyes licensing; academics seek collaborations. Real-world case: Similar to CAR-T advances, but simpler antibody format accelerates development.Université de Montréal press release.
Path to Clinic: Patents, Trials, and Challenges Ahead
Patents on human SLAMF6 mAbs pave the way for Phase I trials in solid/blood cancers, targeting PD-1 non-responders. Timeline: 2-3 years to IND filing, per IRCM vision. Risks: Off-target effects, but SHP-1 specificity mitigates. Solutions: Combo regimens, biomarkers for Tpex-high tumors.
- Monitor SLAMF6 expression via scRNA-seq.
- Pair with bispecifics or ADCs.
Optimism from mouse efficacy (near-complete regressions) and human cell data.IRCM announcement.
Expert Perspectives and Global Context
Experts praise the cis mechanism novelty, likening it to "internal PD-1." In global terms, complements US/EU efforts (e.g., MD Anderson Tpex studies). Canada's edge: Integrated clinic-research like IRCM.
For aspiring researchers, explore career advice on academic CVs to join such teams.
Future Outlook: Reshaping Cancer Immunotherapy in Canada
By 2030, SLAMF6 inhibitors could enter standard care, boosting survival rates. Higher ed implications: More grants, training programs, jobs via university jobs. Engage via Rate My Professor or higher-ed jobs. This Montreal triumph inspires the next generation.
%20Logo.png&w=128&q=75)
